Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial

ConditionsBreast Cancer Sarcoma Gastric Cancer Lung Cancer Head and Neck Cancer Colorectal Cancer Ovarian Cancer Liver Cancer Genitourinary Cancer Gynecologic Cancer Urinary Bladder Cancer Leukemia Lymphoid Leukemia Myeloma Multiple Prostate Cancer Pancreas Cancer Non-hodgkin Lymphoma Hodgkin Lymphoma Brain Cancer Melanoma Mycosis Fungoides Kidney Cancer

Trial statusRecruiting

Trial phasePhase 2

Trial typeInterventional

Biological sexAll

Age18+

SponsorUniversity of California, Irvine

About this trial

This is a phase 2a, randomized, double-blinded, placebo-controlled pilot clinical trial determining the impact of riluzole therapy on circulating brain derived neuropathic factor (BDNF) levels in cancer survivors (recently completing prior treatment regimens) or patients who have received whole brain radiation for benign or malignant tumors with cancer related cognitive impairment.

Eligibility criteria

Qualifiers

Cohort-specific inclusion for male and female patients.

Breast cancer exposed to treatment including chemotherapy, radiotherapy, surgery and/or other breast cancer interventions.

Non-breast cancer patients exposed to anthracyclines- or platinum-containing chemotherapy within the past 3 years.

Non-breast cancer patients exposed to other anticancer therapies within the past 3 years.

Disqualifiers

Cohort A (no prior cranial radiation)

History of or current presence of primary brain tumors or brain metastases.

Cohort B (prior cranial radiation)

Diagnosed with high grade glioma.

Trial design

Treatments tested in this trial

Riluzole
Placebo

Treatment groups

75 Participants

are divided into 2 treatment groups

Sponsors and collaborators

University of California, Irvine

Lead sponsor

Source ClinicalTrials.gov